Tiziana life sciences initiates program to develop intranasal foralumab in type 1 diabetes

New york, april 18, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that it is initiating a program to develop intranasal foralumab for the treatment or prevention of type 1 diabetes.
TLSA Ratings Summary
TLSA Quant Ranking